Folgen
George Dalekos
George Dalekos
Prof. of Medicine, National Expertise Center in Autoimmune Liver Diseases, University of Thessaly
Bestätigte E-Mail-Adresse bei med.uth.gr - Startseite
Titel
Zitiert von
Zitiert von
Jahr
Simplified criteria for the diagnosis of autoimmune hepatitis
EM Hennes, M Zeniya, AJ Czaja, A Parés, GN Dalekos, EL Krawitt, ...
Hepatology 48 (1), 169-176, 2008
22742008
Incidence of inflammatory bowel disease across Europe: is there a difference between north and south Results of the European collaborative study on inflammatory bowel disase …
Gut 39, 690-697, 1996
16041996
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
HSA Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal ...
New England Journal of Medicine 384 (12), 1113-1124, 2021
13442021
EASL clinical practice guidelines: autoimmune hepatitis
European Association for the Study of The Liver
Journal of hepatology 63 (4), 971-1004, 2015
10362015
EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study
KK Ray, B Molemans, WM Schoonen, P Giovas, S Bray, G Kiru, J Murphy, ...
European journal of preventive cardiology 28 (11), 1279-1289, 2021
6652021
Peginterferon plus adefovir versus either drug alone for hepatitis delta
H Wedemeyer, C Yurdaydìn, GN Dalekos, A Erhardt, Y Çakaloğlu, ...
New England Journal of Medicine 364 (4), 322-331, 2011
5572011
Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis
TJ Weismüller, PJ Trivedi, A Bergquist, M Imam, H Lenzen, CY Ponsioen, ...
Gastroenterology 152 (8), 1975-1984. e8, 2017
5092017
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
E Kyriazopoulou, G Poulakou, H Milionis, S Metallidis, G Adamis, ...
Nature medicine 27 (10), 1752-1760, 2021
5032021
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy
G Papatheodoridis, G Dalekos, V Sypsa, C Yurdaydin, M Buti, J Goulis, ...
Journal of hepatology 64 (4), 800-806, 2016
4902016
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis
JZ Liu, JR Hov, T Folseraas, E Ellinghaus, SM Rushbrook, NT Doncheva, ...
Nature genetics 45 (6), 670-675, 2013
4462013
Late HDV RNA relapse after peginterferon alpha‐based therapy of chronic hepatitis delta
B Heidrich, C Yurdaydın, G Kabacam, BA Ratsch, K Zachou, B Bremer, ...
Hepatology 60 (1), 87-97, 2014
3302014
Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience
HL Tillmann, J Hadem, L Leifeld, K Zachou, A Canbay, C Eisenbach, ...
Journal of viral hepatitis 13 (4), 256-263, 2006
3262006
The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B
GV Papatheodoridis, R Idilman, GN Dalekos, M Buti, H Chi, ...
Hepatology 66 (5), 1444-1453, 2017
3172017
Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics
NK Gatselis, K Zachou, GK Koukoulis, GN Dalekos
World journal of gastroenterology: WJG 21 (1), 60, 2015
2832015
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
R Fan, G Papatheodoridis, J Sun, H Innes, H Toyoda, Q Xie, S Mo, ...
Journal of hepatology 73 (6), 1368-1378, 2020
2592020
autoimmune hepatitis–current management and challenges
K Zachou, P Muratori, GK Koukoulis, A Granito, N Gatselis, A Fabbri, ...
Alimentary pharmacology & therapeutics 38 (8), 887-913, 2013
2432013
COVID-19 mortality risk assessment: An international multi-center study
PA Bertsimas D, Lukin G, Mingardi L, Nohadani O, Orfanoudaki A, Stellato B ...
PLoS 15 (12), e0243262, 2020
237*2020
Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of …
K Zachou, N Gatselis, G Papadamou, EI Rigopoulou, GN Dalekos
Journal of hepatology 55 (3), 636-646, 2011
2282011
Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease
K Zachou, E Rigopoulou, GN Dalekos
Journal of autoimmune diseases 1, 1-17, 2004
2162004
Increased serum levels of interleukin-1β in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients?
GN Dalekos, M Elisaf, E Bairaktari, O Tsolas, KC Siamopoulos
Journal of Laboratory and Clinical Medicine 129 (3), 300-308, 1997
2161997
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20